This is great news for patients and family members in the Exon 20 Group, and we are delighted to share it....
Special Message from Ellen Ivey, National Advocacy Policy Director, Janssen Biotech Inc., on behalf of Janssen CarePath Savings Program for RYBREVANT (amivantamab-vmjw)) Patients:
To help ensure that you have the most current information to share with those who contact your organization for medication cost support, I am sending you this update to let you know that RYBREVANT™ (amivantamab-vmjw) is now included in the Janssen CarePath Savings Program. Eligible patients pay just $5 for each infusion and receive savings on their
out-of-pocket medication costs, including deductible, co-pay, and co-insurance for their Janssen medication, up to a $26,000 maximum program benefit per calendar year. There is no income requirement.
This program is only for people age 18 or older using commercial or private health insurance for their Janssen medication. This includes plans from the Health Insurance Marketplace. These programs are not for people who use any state or federal government-funded healthcare program. Examples of these programs are Medicare, Medicaid, TRICARE, Department of Defense, and Veterans Administration. Patients may not seek payment for the value received from these programs from any health plan, patient assistance foundation, flexible spending account, or healthcare savings account. Patients must meet the program requirements every time they use these programs. Program terms will expire at the end of each calendar year. These programs may change or end without notice, including in specific states.
Support may be available for patients using government-funded healthcare programs or for patients without insurance coverage. Janssen CarePath can help identify foundations that may be able to assist your patients.* Patients can call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728) or visit JanssenCarePath.com for more information on affordability programs that may be available.